119 related articles for article (PubMed ID: 10852082)
21. A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting.
Roila F; Basurto C; Minotti V; Ballatori E; Tonato M
Cancer Chemother Pharmacol; 1986; 18(1):88-9. PubMed ID: 3757163
[TBL] [Abstract][Full Text] [Related]
22. Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research.
Roila F
Oncology; 1996 Jun; 53 Suppl 1():65-72. PubMed ID: 8692554
[TBL] [Abstract][Full Text] [Related]
23. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
24. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
[TBL] [Abstract][Full Text] [Related]
25. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
[TBL] [Abstract][Full Text] [Related]
26. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
27. Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Pizzo BA; Pisters KM; Miller VA; Grant SC; Baltzer L; Hinckley L; Kris MG
Support Care Cancer; 1999 Jan; 7(1):44-6. PubMed ID: 9926974
[TBL] [Abstract][Full Text] [Related]
28. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
[TBL] [Abstract][Full Text] [Related]
29. Effective control of cisplatin induced emesis by combination drug regimen.
Misra R; Agarwal N
Indian J Cancer; 1994 Mar; 31(1):19-22. PubMed ID: 8063331
[TBL] [Abstract][Full Text] [Related]
30. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
31. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Ballatori E; Roila F; Berto P; De Angelis V; Neri C; Olivieri A; Tonato M; Del Favero A
Pharmacoeconomics; 1994 Mar; 5(3):227-37. PubMed ID: 10146897
[TBL] [Abstract][Full Text] [Related]
32. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Kris MG; Cubeddu LX; Gralla RJ; Cupissol D; Tyson LB; Venkatraman E; Homesley HD
Cancer; 1996 Nov; 78(10):2193-8. PubMed ID: 8918414
[TBL] [Abstract][Full Text] [Related]
33. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
34. [The control of chemotherapy-induced nausea and vomiting].
Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
[TBL] [Abstract][Full Text] [Related]
35. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
36. A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen.
Meyer BR; O'Mara V; Reidenberg MM
J Clin Oncol; 1987 Dec; 5(12):1994-7. PubMed ID: 3316518
[TBL] [Abstract][Full Text] [Related]
37. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.
Yarboro CH; Wesley R; Amantea MA; Klippel JH; Pucino F
Ann Pharmacother; 1996; 30(7-8):752-5. PubMed ID: 8826554
[TBL] [Abstract][Full Text] [Related]
38. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
39. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
40. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
Roila F; Tonato M; Basurto C; Picciafuoco M; Bracarda S; Donati D; Malacarne P; Monici L; Di Costanzo F; Patoia L
J Clin Oncol; 1989 Nov; 7(11):1693-700. PubMed ID: 2681556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
